June 14, 2018

New OICR President and Scientific Director comments on breakthroughs in breast cancer T-cell immunotherapy

Dr. Laszlo Radvanyi

For the first time, a patient’s late-stage breast cancer has been successfully treated with T-cell immunotherapy. This cutting-edge approach, which is currently in clinical trials in the U.S., modified the patient’s naturally-occurring immune cells to fight her tumours that had spread throughout her body. The patient has been cancer free for the past two years and her remarkable tumour regression represents the potential impact of this new immunotherapeutic approach.

Continue reading – New OICR President and Scientific Director comments on breakthroughs in breast cancer T-cell immunotherapy

May 1, 2018

Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi

Dr. Laszlo Radvanyi

Toronto (May 1, 2018) – Mr. Tom Closson, Chair of the Ontario Institute for Cancer Research’s (OICR) Board of Directors, today welcomed to the Institute Dr. Laszlo Radvanyi, OICR’s new President and Scientific Director. Radvanyi was selected after an extensive international search and has extensive oncology-related experience from his time spent in industry, with a particular focus in immuno-oncology. Radvanyi will work with the Ontario cancer research community, and OICR’s commercialization partner FACIT, to see that Ontario’s best innovations are reaching cancer patients as quickly as possible.

Radvanyi joins OICR from EMD Serono (Merck KGaA, Darmstadt Germany), where he was a Senior Vice President, Global Senior Scientific Advisor in Immunology and Immuno-Oncology. There he played a central scientific advisory role, facilitating major academic centre alliances and ran EMD Serono’s CAR T-cell program, in partnership with Intrexon. He also served as Global Head of the Immuno-Oncology Translational Innovation Platform, where he was instrumental in rebuilding immuno-oncology research at the company, hiring new world-class scientific staff, as well as pruning and re-orienting the discovery pipeline.

Continue reading – Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi